2490552-52-6
2490552-52-6
Chemical Structure
Etentamig
Synonym(s): ABBV-383; TNB 383B
- CAS No.: 2490552-52-6
- Molecular Weight:(123.8 kDa)
SMILES: [Etentamig]
Biological Activity: Etentamig (ABBV-383; TNB 383B) is a T cell engager targeting BCMA and CD3. Etentamig redirects T cell-mediated cytotoxicity by binding BCMA (Kd ≈ 0.7 nM) and activating the T cell co-receptor CD3 (Kd = 1.3 μM), mediates BCMA-specific plasma cell killing and target cell lysis, and has low-activation properties that decouple T cell activation from cytokine release. Etentamig exhibits anti-myeloma efficacy and can be used for research on relapsed/refractory multiple myeloma[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Etentamig | 99% | Etentamig (ABBV-383; TNB 383B) is a T cell engager targeting BCMA and CD3. Etentamig redirects T cell-mediated cytotoxicity by binding BCMA (Kd ≈ 0.7 nM) and activating the T cell co-receptor CD3 (Kd = 1.3 μM), mediates BCMA-specific plasma cell killing and target cell lysis, and has low-activation properties that decouple T cell activation from cytokine release. Etentamig exhibits anti-myeloma efficacy and can be used for research on relapsed/refractory multiple myeloma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. D'Souza A, et al. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Nov 01;40(31):3576-3586. [Content Brief]
- [2]. Foureau DM, et al. Ex vivo efficacy of BCMA-bispecific antibody TNB-383B in relapsed/refractory multiple myeloma. EJHaem. 2020 Jul;1(1):113-121. [Content Brief]
